Chinese residents of Malaysian ‘ghost city' and indebted developer spot a few green shoots
Advertisement
Before he began investing in his three units almost a decade ago, Li checked out the property at a 'prosperous' time.
'When they started sales, ads were going up all over Guangdong province, so I came to visit,' he recalled. 'Lots of people were here then, plus shops, restaurants and the hotel were all open.'
Today, his properties still sit high above a residents-only outdoor pool surrounded by palm gardens. Beyond the gardens lies an artificial beach along the calm Straits of Johor overlooking Singapore.
But Li has nothing good to say about the place any more.
Advertisement
The 26,000-unit Forest City – set off from urban Johor Bahru on an artificial spit of land near the tip of the Malaysian peninsula – lacks a supermarket, which is inconvenient when he and his children, aged seven and eight, need groceries not available at the local convenience store, Li grumbled. A shopping centre trip requires 30 to 40km (18 to 25 miles) of car travel.
Standing beside the tower's basketball court on a muggy Monday night in February, Li said Forest City's retailers enjoyed better fortunes before the Covid-19 pandemic. Just a handful of shops visibly operate now in the 3 sq km (1.16 square mile) compound. Trash easily accumulates in public spaces.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AllAfrica
2 days ago
- AllAfrica
WWIII without bullets: everyone loses in Trump's trade war
As US President Donald Trump enters his second term, his aggressive trade policy has reignited what many are calling a global economic conflict—a de facto World War III without bullets. New tariffs rolled out in August 2025, with more in the works, are shaking global markets, straining supply chains and threatening livelihoods across continents. Unlike conventional warfare, this trade war is fought with tariffs, retaliation and uncertain trade deals. But the impact is no less severe. From factory workers in Asia to farmers in North America, millions are caught in the crossfire. Trump's latest wave of tariffs has sent shockwaves through the business world. Companies from Detroit to Dhaka are scrambling to adjust to shifting costs, delayed shipments, and volatile demand. Firms are once again hesitating to hire, expand, or invest. Some are already scaling back production. Small and medium-sized enterprises—especially in export-dependent economies—are suffering most. As one supply chain manager in Vietnam put it: ' We've spent the last two years rebuilding after Covid and inflation. Now we're tearing it all down again because of this trade war. ' Rising input costs and shrinking demand are leading many businesses to cut jobs, not create them. The economic promises behind Trump's tariffs—protecting American jobs and revitalizing domestic industries—are clashing with the reality on the ground. US farmers are facing new retaliatory tariffs from China, threatening their already-precarious position in global markets. In developing countries, layoffs are widespread, especially in garment manufacturing, electronics assembly and food processing industries that rely heavily on exports. This trade war is not just a fight between the US and China. Its ripples reach deep into the Global South, where countries that depend on trade with major economies are being dragged into the fray. In Bangladesh, Cambodia and Nigeria, factories are closing. Port activity is slowing. Currencies are destabilizing. Millions who had only recently climbed out of poverty are now seeing their futures collapse. For developing nations, trade is not a chess piece in a geopolitical contest—it's a lifeline. They are the invisible casualties of this economic conflict. Even the US's closest allies haven't been spared. Canada is once again facing U.S. tariffs, particularly on aluminum, solar panels and some agricultural products. While Canada remains a party to the USMCA, the agreement doesn't shield it from unilateral actions by the US president under Section 232 of the Trade Expansion Act—allowing tariffs on the basis of 'national security.' This proves that even formal trade agreements offer little real protection in a system dominated by unpredictable, politically motivated policies. Trump's ongoing trade war has undermined decades of American leadership in building a rules-based trading system. The US once led the push for open markets, global cooperation, and dispute resolution mechanisms. Now, it has become one of the leading sources of uncertainty—with tariffs as threats, not tools, and agreements treated as optional rather than binding. If the US can impose or ignore rules at will, what incentive do other countries have to stick to them? Once again, the World Trade Organization (WTO) is watching from the sidelines. With its dispute resolution body still crippled and no meaningful reform in sight, the WTO has failed to respond to this growing crisis. Without a functioning enforcement system, the rules of global trade are reduced to suggestions—and global trust is crumbling. At the core of Trump's approach is a zero-sum philosophy: that any gain by another country must be a loss for the US. But that doesn't match how the modern global economy actually works. One country's import is another's export. One company's supplier is another's customer. Disrupting trade damages everyone in the chain, especially workers at the bottom. Trade, when cooperative and fair, is a positive-sum system. But when weaponized for political points, the damage is universal. Trump's second-term tariff war is already causing widespread disruption. If left unchecked, it risks pushing the world economy toward deeper fragmentation, financial instability, and rising inequality. The promise of global trade has always been mutual growth and shared prosperity. But today, it is being twisted into a tool of confrontation. If trade becomes war, everyone loses. Businesses lose clarity. Workers lose income. Developing nations lose hope. It's not too late to turn back. But doing so will require bold leadership, trust in international institutions, and a renewed commitment to trade not as a weapon—but as a bridge.
South China Morning Post
5 days ago
- South China Morning Post
Shenzhen's Yuanhua eyes Hong Kong for assembly plant, IPO in overseas surgical robot push
Shenzhen surgical robot start-up Yuanhua Tech plans to set up an assembly facility in Hong Kong to grow overseas sales and aims to float shares on the city's bourse to fund development, according to its founder. In 2022, the company received approval from China's National Medical Products Administration to sell self-developed orthopaedic robot systems for total and partial knee and hip joint replacement surgeries, founder and chairwoman Li Aili said in an interview. She expected that the firm, established in 2018, would receive approval next month to market its artificial disc replacement and trauma joint replacement surgery robots. Having sold some approved systems to hospitals on the Chinese mainland and in Hong Kong, Yuanhua Tech wants to expand to overseas markets, especially Southeast Asia and Europe, with 'made in Hong Kong' products, Li said. 'I am looking for suitable manufacturing premises in Tai Po, since our facility at Hong Kong Science and Technology Park in Pak Shek Kok, while good for designing prototypes, is not suitable for large-scale production,' she said. Yuanhua Tech founder and chairwoman Li Aili. Photo: Handout The company plans to ship components made at its plant in Nanshan, Shenzhen to Hong Kong where robots for overseas clients would be assembled.
RTHK
6 days ago
- RTHK
Settlement reached over Covid-19 vaccines
Settlement reached over Covid-19 vaccines The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. File photo: RTHK American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said on Friday. The royalties would amount to a "single-digit" percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech the non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which has worked with CureVac since 2020 to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a 1 percent royalty on US sales of flu, Covid and "related combination mRNA vaccine products". CureVac sued German rival BioNTech in 2022, arguing that it had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in collaboration with Pfizer. Unlike traditional vaccines that contain some form of the dead or inactivated target virus, mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based Covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal "set a framework for resolving ongoing patent disputes outside the US". In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. (AFP)
